Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

University of Pittsburgh

Status and phase

Terminated

Phase 1

Conditions

Renal Cell Carcinoma

Treatments

Drug: Hydroxychloroquine (HC)

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01144169

10-029

Details and patient eligibility

About

The main goal of this research study is to determine whether treating patients with renal cell cancer with hydroxychloroquine before surgery can make the cancer easier to kill. Another goal is to see how the study drug affects the body's immune cells which fight cancer cells.

Full description

Autophagy is a cellular survival mechanism that protects from stress-induced programmed death. Autophagy may enable renal cancer to escape from cytokine therapy, cytotoxic chemotherapy or targeted agents. Hydroxychloroquine prevents autophagy by blocking acidification of lysosomes, and is being studied in clinical trials as a means of enhancing of cancer therapy. This phase Ib clinical trial will test the hypothesis that pre-operative exposure to HC reduces biologic markers of autophagy in peripheral blood, normal kidney and renal cancer specimens obtained at the time of nephrectomy. These data will be used in the design and pharmacodynamic monitoring of future therapeutic trials of HC in combination with high dose interleukin-2 and other systemic therapies for advanced RCC.

Enrollment

7 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects with suspected primary or metastatic RCC (stage 1-IV) with planned nephrectomy or partial nephrectomy.
ECOG performance status ≤1
Normal renal, hepatic, and hematologic function at the time of enrollment as evidenced by:
- Serum creatinine level ≤1.5 the upper limits of normal (ULN)
- Serum total bilirubin level ≤1.5 X ULN
White blood cell count > or = 3.5x109/ml per ml and platelet count ≥ 100x109 per ml
Age >18 years.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Subjects who have received chemotherapy for any diagnosis within 12 months prior to study entry.
Prior use of radiotherapy or investigational agents for RCC.
Concurrent malignancies with evidence of active or measurable disease except non-melanoma skin cancer
Inability to adhere to study and/or follow-up procedures
History of allergic reactions or hypersensitivity to the study drug (hydroxychloroquine) or current therapy with the study drug for other reasons.
Other concurrent experimental therapy.
The effects of HC on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. All females of childbearing potential must have a blood test or urine study within two weeks prior to registration to rule out pregnancy. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately. If a man impregnates a woman while participating in this study, he should inform his treating physician immediately as well.
HIV-positive patients are not excluded from the study. However, for patients receiving combination anti-retroviral therapy, the potential impact of pharmacokinetic interactions with HC is unknown. Therefore, HIV-positive patients actively receiving anti-retroviral therapy are excluded from the study.
Patients with psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist who agrees to monitor the patient for exacerbations.
Patients requiring the use of enzyme-inducing anti-epileptic medication that includes: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded. Hydroxychloroquine is known to affect the CYP2D6 metabolic pathway. A list of drugs with potential interaction is included in Appendix H.
Patients with previously documented macular degeneration or diabetic retinopathy are excluded.
Patients with known glucose-6-phosphate dehydrogenase (GP6D) deficiency
EKG with QTc >500 msec at baseline (average of 3 determinations at 10 minutes interval). Subjects with ventricular pacemaker for whom QT interval is not measurable will be eligible on a case-by-case basis.